Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.56 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | LIPE | Q05469 | 8/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.52 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20988227 | 0.87 | MAPT (0.61) | MAPTNPSR1LMNARAB9AIDO1 | |
| SCHEMBL11351938 | 0.86 | MAPT (0.69) | MAPTNPSR1LMNARAB9ATHRB | |
| SCHEMBL20988347 | 0.83 | IDO1 (0.63) | MAPTNPSR1LMNARAB9AIDO1 | |
| SCHEMBL3106187 | 0.82 | CA1 (0.50) | LMNA | |
| SCHEMBL11383589 | 0.81 | LIPE (0.65) | MAPTNPSR1LMNARAB9ADAGLA | |
| SCHEMBL8576331 | 0.81 | MAPT (0.65) | MAPTNPSR1LMNARAB9ATHRB | |
| SCHEMBL20988226 | 0.81 | LMNA (0.65) | MAPTNPSR1LMNARAB9AIDO1 | |
| SCHEMBL1153375 | 0.81 | THRB (0.53) | MAPTNPSR1LMNARAB9AIDO1 | |
| SCHEMBL1153696 | 0.81 | L3MBTL1 (0.52) | MAPTNPSR1LMNARAB9AIDO1 | |
| SCHEMBL1154644 | 0.81 | THRB (0.53) | MAPTNPSR1LMNARAB9AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049643-A1 | NOX4 INHIBITORS AND METHODS OF MAKING AND USING SAME | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2025-03-06 | — | — | WO | disclosed |
| EP-3481801-B1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | UNIV ARIZONA (US) | 2023-09-06 | — | — | EP | disclosed |
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSIT (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNVERSITY OF ARIZONA | 2019-05-09 | — | — | US | disclosed |
| US-8299262-B2 | Pyridylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20110015065-A1 | Substituted Sulfonic Acid Amide Compounds | BASF SE (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2252590-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2010-11-24 | — | — | EP | disclosed |
| US-20100249077-A1 | Pyridylmethyl-Sulfonamide Compounds | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
| EP-2231605-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009101082-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009071448-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071449-A1 | PYRIDYLMETHYL-SULFONAMIDE COMPOUNDS | BASF SE (DE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654802-B2 | Indoline derivatives and method for using and producing the same | IDO1, IDO2, MMP1 | MAPT 1971/4885NPSR1 119/4885LMNA 1162/4885 |
| US-20110015065-A1 | Substituted Sulfonic Acid Amide Compounds | STS, NAPA, NAAA | MAPT 3640/4885NPSR1 133/4885LMNA 3828/4885 |
| US-20190135746-A1 | INDOLINE DERIVATIVES AND METHOD FOR USING AND PRODUCING THE SAME | IDO1, INMT, MMP1 | MAPT 1638/4885NPSR1 61/4885LMNA 1099/4885 |
| US-20100249077-A1 | Pyridylmethyl-Sulfonamide Compounds | CBR3, CBR1, CBS | MAPT 4200/4885NPSR1 305/4885LMNA 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.